T he annual incidence of stroke is approximately 700 000 per year in the United States. 1 Ischemic strokes account for 80% of these strokes. 1 The high incidence and prevalence of stroke as well as the great variation in clinical outcome have led to an interest in identifying accurate predictors of outcome.
Numerous clinical variables have been identified as potential predictors of clinical outcome. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Age 2,4 -7,9 -12 and severity of presenting clinical deficit 2-4,6,7,10 -13 are consistently found to be predictive of outcome. Many other predictors have been reported to have a univariable relationship with outcome, but their multivariable relationship to outcome is less clear because of conflicting results in the literature. 3-6,10 -13 Infarct volume, as measured by CT, has also been shown to correlate with clinical outcome. 14, 15 This relationship appears to be modest and to account for only a limited amount of the variance in outcome. Very few studies have examined a combination of clinical and imaging information in an attempt to predict clinical outcome in acute ischemic stroke patients. 16 -19 The combination of clinical variables and imaging variables as predictors of stroke outcome in a multivariable risk adjustment model may be useful in evaluating stroke outcomes in both prospective and retrospective clinical research as well as in patient care.
The purpose of this study was to determine the multivariable relationship between infarct volume, several clinical patient characteristics, and outcomes 3 months after ischemic stroke. This study is a test of the hypothesis that imaging and clinical information together could predict outcome with the use of subacute infarct volume data.
Subjects and Methods

Study Population
The stroke patients used for this analysis were participants in the Randomized Trial of Tirilazad Mesylate in patients with Acute Stroke (RANTTAS). 20 The RANTTAS trial was a multicenter, randomized, double-blinded, vehicle-controlled trial to evaluate the efficacy and safety of intravenous tirilazad mesylate in patients with acute ischemic stroke. Eligible patients were treated within 6 hours of symptom onset at 1 of 27 North American centers between May 1993 and December 1994. The primary outcome measures for this trial were the Barthel Index (BI) and Glasgow Outcome Scale (GOS) scores collected at 3 months. National Institutes of Health Stroke Scale (NIHSS) scores were also collected at 3 months as an additional key outcome measure. Three-month outcome measurements were obtained by study investigators who were trained to perform the measurements accurately and consistently. A random sample of half of all fully eligible patients were selected at study entry to submit head CT scans for volumetric measurement of infarct size at 7 to 10 days with planimetric techniques. 20 A total of 556 fully eligible patients were enrolled in the trial, and 256 submitted acute and follow-up head CT scans for central evaluation. All 256 fully eligible patients with prospectively collected CT and clinical measures from the RANTTAS trial were included in this study. Since treatment with tirilazad mesylate did not have an effect on outcome, 20 the 2 treatment groups were combined for this analysis.
Independent Variables
Independent variables for the model were identified prospectively to avoid increased risk of type I errors and overfitting of the predictive model. First, a detailed literature review was performed to identify the published relationships between clinical predictors of stroke outcome. More than 60 variables have been examined in the literature for their relationship to stroke outcome. 2-12,14 -19 The articles were read and their bibliographies reviewed. We then evaluated the frequency of specific stroke outcomes in the data set. In an attempt to avoid overfitting, we limited the number of candidate variables to 7 on the basis of the size of the study population and number of outcomes. 21 These variables were selected on the basis of the strength of the relationship to stroke outcome in the published literature, availability in the RANTTAS data set, and investigator judgment. Six clinical variables and 1 imaging variable were chosen. These prespecified variables and any dichotomization of these variables were identified before we examined any relationships in the data set, and at no time during the analysis were any changes made to the variables.
The variables are shown in Table 1 . The NIHSS is a valid and reliable rank order scale that measures 11 categories of neurological deficit by neurological examination in stroke patients. 22 The NIHSS score was determined by personnel trained and certified in the proper use of the scale. Premorbid stroke and diabetes mellitus were dichotomized as present or absent by history. The degree of prestroke disability was estimated according to clinical history with the GOS, a standard and validated scale that measures 5 categories of disability in patients with neurological injury. 23 The GOS was then dichotomized as the presence or absence of any disability before stroke to reduce the total number of degrees of freedom in the final model. Ischemic stroke subtype was determined at 7 to 10 days after stroke according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. 24 This was then dichotomized as small-vessel occlusive disease or not small-vessel occlusive disease on the basis of evidence that patients with small-vessel infarcts have better outcome. 8, 13 The imaging variable was infarct volume, as determined by noncontrast head CT scan obtained 7 to 10 days after stroke and measured in cubic centimeters.
Outcome Variables
The outcomes for the model were prespecified. These included 3 commonly used clinical outcome measures in stroke trials. The NIHSS 22 and the GOS 23 are both well-established, validated measures of clinical outcome. The BI is a standard and well-validated scale that measures ability to complete 10 basic activities of daily living. 25 Each of the 3 outcome scales was prospectively dichotomized at 2 different points on the scale. One point identifies excellent outcome (full or nearly full recovery) versus worse than excellent outcome (all else). The second cut point identifies very poor outcome (nursing home level disability or death) versus better than very poor outcome (all else). The definitions are shown in Table 1 . Dichotomization provides outcomes that are easily understood by clinicians and patients, and the literature provides significant face validity for all but 1 of these defined outcomes, which have been used in numerous clinical trials. 12, 20, 26 We are unaware of any clinical trials that have used severe disability or death measured by NIHSS as an outcome. The Ͼ20 cutoff for the NIHSS in the very poor outcome model was based on the clinical judgment of the authors as well as other analyses that used 20 as a cut point. 12 
Missing Variables
If the outcome variable required by the model was missing, the subject was eliminated from the analysis (NIHSS, nϭ35; BI, nϭ27; GOS, nϭ27). If either the initial NIHSS score was missing (nϭ5) or the CT infarct volume was missing (nϭ3), the subject was eliminated from the analysis. This resulted in a total of 221 patients with an NIHSS outcome score, but only 215 subjects were analyzed in the NIHSS models since 1 or both of the aforementioned missing variables were missing (2 patients were missing both initial NIHSS and infarct volume). A total of 229 patients had BI outcome scores and GOS outcome scores, but only 222 were used in the BI models and GOS models because of missing predictor variables (1 patient was missing both initial NIHSS and infarct volume in both sets of models).
Follow-up CT infarct volume measures that occurred outside of the window of 7 to 10 (Ϯ1) days were imputed as infarct volumes for 21 subjects who were imaged slightly outside of this window. These included 10 patients imaged before the window (earliest was day 3) and 8 patients imaged after the window, with all but 1 being within 30 days (latest was day 78). The remainder of the patients had incomplete data, and exact timing of imaging is unknown.
Analysis
The rigor of variable selection (described above) and the analysis were designed to avoid overfitting the models in the data set. After prespecification of the predictor and outcome variables, we developed and tested 6 distinct models using the RANTTAS data set. We used restricted cubic splines to allow nonlinear covariate relationships with age to be assessed. This is a method of allowing a continuous variable to be nonlinear in the analysis, therefore avoiding linearity assumptions. Because of limitations in size of our data set, we did not allow for nonlinearity of the NIHSS or infarct volume predictors. A model was developed for each of the 3 outcome measures (NIHSS, BI, GOS) for each of the 2 levels of outcome (excellent, very poor). For each of the 6 models, comparison models including only the clinical variables and only the imaging variable were also evaluated. We compared the performance of the combined model (clinical and imaging variables) with the clinical model (clinical variables only) and the imaging model (infarct volume only). The weights of each of the predictive variables for each model were determined by multivariable logistic regression techniques. Model discrimination was assessed by area under the receiver operator characteristic (ROC) curves, which was computed by the nonparametric method. 27 The area under the ROC curve is a measure of overall predictive discrimination, which is defined in this study as the ability to separate those patients who had excellent outcome from those who did not have excellent outcome, or those who had very poor outcome from those who did not have very poor outcome. An ROC curve area of 0.5 indicates no discrimination, and an ROC curve area of 1.0 indicates perfect discrimination. The area under the ROC curves for the nested models (combined versus clinical or imaging models) were compared with likelihood ratio 2 statistics. 28 Calibration was assessed with calibration curves. 21 Calibration is the ability to predict probabilities across all ranges of risk and reflects the reliability or degree of bias of the model. It is illustrated with calibration graphs that plot predicted probability (using the model) against actual probability. In a calibration graph, the line on the 45-degree angle represents perfect calibration (the predicted probability equals the actual probability). The closer the model calibration curve is to the 45-degree line, the better is the calibration.
Bootstrap validation of the combined model for each of the outcomes was also performed. 29 This is a technique, described in detail by Efron and Gong, 29 in which the model is developed with all subjects and then reanalyzed on repeated random samples of the data set. This method of internal validation assesses how accurately the models will predict outcome in a new similar sample of stroke patients. It assesses whether or not the model is biased because of overfitting of the model. Resampling occurred 100 times for each bootstrap validation, and age was allowed to be nonlinear in each model by using a restricted cubic spline with 3 knots. All analyses were done with S-Plus 4.5 software (MathSoft Inc).
Results
The patient predictor and outcome characteristics are displayed in Table 2 . The mean age was nearly 69 years, and the median NIHSS score of 10 suggested moderate severity of initial neurological deficit. Approximately one fourth of patients had a history of diabetes mellitus, one fourth had a history of stroke, and one fourth had the small-vessel stroke subtype. Few patients were disabled before the enrolling stroke event. Stroke severity was broadly distributed as measured by both the NIHSS and the infarct volume ( Figure  1) . Eighty-four patients had no visible infarct by head CT obtained at 7 to 10 days. As shown in Table 2 , 14% of patients were dead at 3 months. Excellent outcomes by each of the 3 measures (NIHSS, BI, GOS) were quite common. Very poor outcome, as defined by the NIHSS, was very infrequent.
The multivariable relationship between the 7 predictor variables and each of the 6 outcome variables is shown in Table 3 . For excellent outcome as determined by the NIHSS score of Յ1 at 3 months, the baseline NIHSS score, smallvessel infarct, history of previous stroke, history of diabetes, history of prestroke disability, and infarct volume at 7 to 10 days were all significant predictors. For excellent outcome as determined by the BI (score Ն95) and the GOS (scoreϭ1) at 3 months, age, NIHSS, diabetes, disability, and infarct volume were all significantly predictive of outcome. For very poor outcome, only infarct volume was a significant predictor of NIHSS score of Ն20 or death at 3 months. For very poor outcome as determined by the BI (score Ͻ60 or dead) and by the GOS (score Ͼ2 or dead), age, initial NIHSS score, prior disability (for BI only), and infarct volume were significantly predictive of outcome. The information needed to calculate each regression model is given in the Appendix. Discrimination, as indicated by bootstrap-corrected area under the ROC curve, is shown in Table 4 for models using imaging variables only, clinical variables only, or both clinical and imaging variables combined. The combined model had an area under the ROC curve greater than either of the other 2 models for 5 of the 6 outcomes. For prediction of excellent outcome, the model using NIHSS as a measure of excellent outcome had the best discrimination, with an ROC area of 0.87. For very poor outcome, the model using BI as a measure of very poor outcome had the best discrimination, with an ROC area of 0.88. The uncorrected area under the ROC curve was similar to the bootstrapcorrected data, with the maximum area under the ROC curve being 0.89 for excellent outcome in the NIHSS model and 0.89 for very poor outcome in both the BI model and the GOS model (data not shown). For both the original and the bootstrap-corrected areas, the combined model (clinical and imaging variables) consistently had the greatest ROC area compared with the other 2 models (clinical alone, imaging alone). The likelihood ratio tests were significant for all but 1 comparison of the models.
Calibration graphs for the combined model when predicting excellent outcome and very poor outcome, as measured by NIHSS, are shown in Figure 2 . For excellent outcome as measured by NIHSS (Figure 2A ), the proximity of the bias-corrected calibration curve to the line of identity (ideal) demonstrates that the combined model is well calibrated. The proximity of the bias-corrected line to the apparent line (model performance before bootstrap) demonstrates that overfitting was minimal. Although the calibration curve of the original model is closer to the ideal, the bias-corrected curve (bootstrap validated) is the more valid representation of the likely relationship in other similar data sets since it penalizes for the fact that we derived and validated the models in the same patients. The excellent outcome calibration curves for both BI and GOS were very similar (data not shown). For very poor outcome as measured by the NIHSS (Figure 2B ), the calibration was not quite as good. The very poor outcome model calibration curves for the BI and GOS were similar to the excellent outcome curves (data not shown). To demonstrate that the excellent performance of the combined model was not due to a limited distribution of the probability of an excellent outcome, Figure 3 displays the broad distribution of predicted probabilities for excellent outcome as measured by the NIHSS. The other measures of excellent outcome were distributed similarly (data not shown).
Discussion
There is a strong multivariable relationship between the 7 variables (6 clinical and 1 imaging) and excellent outcome (full or nearly full recovery) and the 7 variables and very poor outcome (nursing home level disability or death) at 3 months after ischemic stroke. The models that include both clinical and imaging predictor information are statistically superior in performance to the models using clinical variables alone or imaging variables alone. The combined models were tested in a heterogeneous stroke population who participated in a multicenter, randomized acute stroke trial. They had a broad distribution of predicted outcome. Bootstrap validation demonstrated the internal validity of the models, which showed excellent discrimination and calibration. Five of the 6 models (excellent outcome models and BI, GOS of the very poor outcome models) had excellent ability to discriminate between outcomes as demonstrated by the area under the ROC curves (see Table 4 ). Model predictions with ROC areas Figure 3 . Frequency distribution of predicted probability of excellent outcome as measured by the NIHSS in the study population. Although a large number of patients had a very high predicted probability of excellent outcome, there was a broad distribution of predicted probabilities. Ͼ0.80 have been endorsed for use in individual predictions. The ability of these models to discriminate outcomes for a disease that has such heterogeneity of characteristics and outcomes is encouraging. The calibrations of the excellent outcome models and 2 of the very poor outcome models (BI, GOS) are nearly ideal, as demonstrated by the calibration graphs. The NIHSS-measured very poor outcome model had an ROC area of 0.79 and poorer calibration than the other models. We believe that the limited number of outcomes by this measure (only 36, as seen in Table 2 ) is responsible for the lesser performance of this model.
Very few previous studies have combined clinical and imaging variables for the purpose of predicting stroke outcomes. Hénon et al 17 combined clinical predictors with information from head CT but did not use infarct volume, which is now well recognized as a predictor of outcome. In this study the investigators evaluated a relatively large number of predictor variables (18) despite a low death rate of 16% (the specified outcome variable), thereby potentially increasing the risk of an overfitted model with poor external validity. 21 Toni et al 18 also evaluated a model that combined clinical and imaging information. Variables in their analysis were chosen by stepwise techniques, which makes the resulting model very sensitive to the characteristics of the development data and is prone to overfitting. 21 A similar approach was taken by Finocchi et al, 19 who combined clinical and imaging variables but categorized infarct volume into 3 categories (no lesion, medium lesion, large lesion). They suggested that since the final size of an infarct cannot be detected on CT for several days after the event, the infarct volume does not improve the predictive ability of such a model. Current availability of new imaging techniques, such as diffusion-weighted MRI, that identify lesion volume in the acute setting 30 -35 may improve our ability to predict stroke outcomes in the acute setting.
There are several limitations of this study. First, this model has only been tested in the data set from which it was derived. It has not been prospectively validated with independent data. We were careful, however, to avoid overspecification of the model by prospectively identifying the independent variables, avoiding stepwise variable selection techniques, retaining all candidate variables in the final model, and limiting candidate variables to no more than 1 for each 10 observations of the least frequent outcome. 21 Our model used each of these techniques, making it unlikely that we have significantly overmodeled the data set. The use of the bootstrap validation to internally validate our model, which penalizes for optimism caused by any overfitting present, demonstrates model stability and suggests that we have not overfit to this single data set.
The fact that infarct volume and stroke subtype data were not collected acutely in the RANTTAS trial limits our ability to use the models in the acute ischemic stroke setting. However, this analysis does provide evidence that imaging and clinical information together can be predictive of 3-month outcome and that together they are more powerful than either alone. These data support future attempts to predict 3-month outcome using measures of infarct volume and stroke subtype, obtained with new imaging technology, in the acute stroke setting.
The small size of the data set and specifically of the outcomes of interest was also limiting. We believe that the small sample limited our power to demonstrate statistically significant relationships between some predictors and outcome (Table 3) in several of the models despite our hypothesis that clinically important relationships exist. We also recognize, however, that some of the differences in strength of relationships of predictors in different models may be related to the fact that we are measuring different outcomes. In addition, sample size likely limited our ability to demonstrate a stronger predictive relationship in the very poor outcome as measured by NIHSS model (with only 36 outcomes).
A model that can predict clinical outcome in acute stroke patients would be potentially useful in a number of ways. Risk adjustment of acute stroke populations could improve clinical research as well as potentially improve the stroke management process. The great heterogeneity of the ischemic stroke population has been well described, 36 -43 as has the difficulty such heterogeneity has imposed on the evaluation of new therapies for stroke patients. 13,44 -46 Patients with ischemic stroke vary considerably in clinical characteristics such as infarct size and location, vascular anatomy, premorbid conditions, age, severity of deficit, previous brain function, and genetic makeup, to name only a few. This heterogeneity is a concern since drug effect may vary across the severity spectrum (treatment by severity interaction), as has been demonstrated in other diseases. 47 Even with strict eligibility criteria, such variables cannot be controlled for in clinical trials without risking the generalizability of the results. 43 The considerable variability in the stroke population, therefore, makes it much more difficult to detect treatment effects since imbalances in important patient characteristics may occur by chance, especially in small trials. DeGraba et al 13 recently suggested the need for stratification by stroke severity in clinical stroke trials since disease severity may affect the clinical outcome. Since the effect of an intervention on outcome may also vary with stroke severity and since the great heterogeneity of the stroke population may conceal treatment effects, risk adjustment models may increase our ability to detect the effects of therapy in clinical research by statistically accounting for this heterogeneity or by providing a single stratification variable (predicted probability of outcome) that allows the consideration of individual severity of disease at the time of clinical trial enrollment.
Knowing expected outcome may also allow improved selection of patients anticipated to respond to therapy. As illustrated in Figure 3 , there may be a proportion of patients who at entry to a trial have a high likelihood of full recovery or a high likelihood of a devastating outcome. Depending on the agent being evaluated, such extreme risk patients may be included or excluded to increase the statistical power for detecting treatment effects. In addition, the appropriateness of eligibility criteria in a trial may depend on outcome and complication risks. A patient who is highly likely to have a full recovery, for example, may not be a good candidate to The estimated probability of the outcome can be estimated for each model using the logistic transformation Yϭ1/1ϩe ϪXb , given Yϭestimated probability and XbϭaϩbX1. . .bpXp using the intercepts and ␤ coefficients listed above for each of the 6 models.
